Zürcher, K., Ballif, M., Kiertiburanakul, S., Chenal, H., Yotebieng, M., Grinsztejn, B., Michael, D., Sterling, T. R., Ngonyani, K. M., Mandalakas, A. M., Egger, M., Pettit, A. C. and Fenner, L. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low‐ and middle‐income countries: a multicohort study. J Int AIDS Soc. 2019; 22(9):e25392

1. Introduction {#jia225392-sec-0005}
===============

In low‐ and middle‐income countries (LMIC), tuberculosis (TB) accounts for approximately 40% of HIV/AIDS‐related deaths among adults, and half of those TB cases are undiagnosed at the time of death [1](#jia225392-bib-0001){ref-type="ref"}. TB predominantly affects the lungs (pulmonary tuberculosis \[PTB\]), but can affect extrapulmonary sites as well (EPTB). Globally, about 25% of all TB cases are estimated to be EPTB [2](#jia225392-bib-0002){ref-type="ref"}. EPTB is a common presentation in HIV‐positive individuals, particularly in those with low CD4 cell counts [3](#jia225392-bib-0003){ref-type="ref"}, [4](#jia225392-bib-0004){ref-type="ref"}. EPTB is most frequently identified in the lymph nodes, pleura, bones and joints, abdomen, meninges and genitourinary tract [5](#jia225392-bib-0005){ref-type="ref"}. TB meningitis is considered the most severe form of EPTB with mortality as high as 70% in low‐income countries [6](#jia225392-bib-0006){ref-type="ref"}.

The diagnosis of EPTB is particularly difficult and is often solely based on clinical signs and symptoms. A bacteriological confirmation of EPTB often requires invasive specimen collection by biopsy or fine needle aspiration [7](#jia225392-bib-0007){ref-type="ref"}, [8](#jia225392-bib-0008){ref-type="ref"}, followed by use of adequate diagnostic tests [9](#jia225392-bib-0009){ref-type="ref"}, [10](#jia225392-bib-0010){ref-type="ref"}. Much progress has been made in developing new diagnostic tests for TB, including the Xpert MTB/RIF and other nucleic acid amplification tests (NAAT), which have higher sensitivity than smear microscopy and can also be used to diagnose both PTB and EPTB [11](#jia225392-bib-0011){ref-type="ref"}. This study assessed diagnostic modalities and TB treatment outcomes of EPTB compared to PTB in HIV‐positive adults in clinical care in antiretroviral therapy (ART) programmes in six International epidemiology Databases to Evaluate AIDS (IeDEA) regions in sub‐Saharan Africa, Asia‐Pacific, Caribbean, Central and South America Central and South America.

2. Methods {#jia225392-sec-0006}
==========

2.1. Study setting and study population {#jia225392-sec-0007}
---------------------------------------

IeDEA ( [www.iedea.org](http://www.iedea.org)) is a large consortium of ART programmes predominantly located in LMIC [12](#jia225392-bib-0012){ref-type="ref"}. ART programmes in six IeDEA regions participated in this study are mostly public but often supported by NGOs or academia: East Africa; Central Africa; West Africa; Southern Africa; Asia‐Pacific; Caribbean, Central and South America.

We reviewed records of consecutive 3165 HIV‐positive patients diagnosed with any form of TB between January 1, 2012 and December 31, 2014 in participating ART programmes. Patient records missing data on sex, date of birth or site of disease were excluded from the analysis (35 records). We studied only adults and excluded paediatric cases (age \<16 years, 396 records). In case of multiple TB episodes, only the patient\'s first episode was included in the study (39 duplicate records deleted). This resulted in the inclusion of 2695 adult HIV‐positive TB patients from 22 ART programmes (Figure [1](#jia225392-fig-0001){ref-type="fig"}).

![Geographical distribution of 22 antiretroviral treatment (ART) programmes treating HIV‐positive patients (≥16 years) in low‐ and middle‐income countries. The proportions of pulmonary (black), mixed pulmonary/extrapulmonary (grey), and extrapulmonary tuberculosis cases (white) diagnosed at each site are indicated in the pie charts; n indicates the number of patients included in the study by IeDEA region; the numbers in parentheses following the country names indicate the number of ART programmes participating in the study by country. EPTB, extrapulmonary tuberculosis; IeDEA, International Epidemiology Databases to Evaluate AIDS;PTB, pulmonary tuberculosis.](JIA2-22-e25392-g001){#jia225392-fig-0001}

2.2. Data collection {#jia225392-sec-0008}
--------------------

Standardized electronic case report forms (CRFs), available in English or French, were used to record age, sex, date of TB diagnosis, site of TB disease, site of EPTB manifestation (predominant organ), start date of TB treatment, body mass index (BMI) at start of TB treatment, ART status at TB diagnosis, CD4 cell count at start of TB treatment, previous history of TB, TB drug resistance, results from TB diagnostic tests (smear microscopy, culture, Xpert MTB/RIF and other NAAT) and TB treatment outcomes [13](#jia225392-bib-0013){ref-type="ref"}. All data were collected using REDCap ( [www.project-redcap.org](http://www.project-redcap.org)) [14](#jia225392-bib-0014){ref-type="ref"}. Local IeDEA site investigators completed CRFs for TB patients. Data were entered between January 2012 and January 2016. During data collection, routine audits were made to ensure data quality [15](#jia225392-bib-0015){ref-type="ref"}. Furthermore, we used programme‐level data previously collected in the same ART programmes in 2012 [16](#jia225392-bib-0016){ref-type="ref"}.

2.3. Definitions {#jia225392-sec-0009}
----------------

We categorized TB as PTB (involving the lungs only), mixed PTB/EPTB and EPTB only [5](#jia225392-bib-0005){ref-type="ref"}. For binary outcome analyses, we used the categories PTB and EPTB (includes mixed PTB/EPTB cases) as previously defined [17](#jia225392-bib-0017){ref-type="ref"}. Miliary TB was categorized as EPTB. Furthermore, we categorized bacteriological confirmation as "test performed" if at least one of the tests (smear microscopy, culture, Xpert MTB/RIF and/or other NAATs) was performed regardless of whether the result was positive or negative; "positive" bacteriological confirmation (any positive test result); "negative" (all performed tests were negative); and "no test performed." TB treatment outcomes were categorized as cured, treatment completed, treatment failed, died, lost to follow‐up (LTFU) and not evaluated [5](#jia225392-bib-0005){ref-type="ref"}. The category "not evaluated" included patients who were still on treatment, transferred out and those whose treatment outcome was unknown. The category "treatment success" included cured patients and patients who completed TB treatment.

2.4. Statistical analyses {#jia225392-sec-0010}
-------------------------

We used descriptive statistics to characterize both programme‐level and patient‐level data, as well as diagnostic modalities. Differences between groups were assessed using chi‐square, Fisher\'s exact or Wilcoxon rank‐sum tests as appropriate. We used univariate and multivariate logistic regressions to assess risk factors for mortality and LTFU during TB treatment. These associations were presented as unadjusted odds ratios (ORs) and ORs adjusted (aORs) for age, sex, BMI at start of TB treatment, previous history of TB, ART status at TB diagnosis and CD4 cell counts at start of TB treatment, taking into account heterogeneity across regions (clustering by treatment programmes). In separate models, we obtained the estimates for EPTB sites, (adjusted for the same co‐variates). Patients without documented treatment outcomes were excluded from the primary analysis. However, we performed a sensitivity analysis considering patients LTFU as having died. To account for missing data we used multiple imputations by chained equations to impute missing BMI, ART status at TB diagnosis, CD4 cell counts at start of TB treatment and previous history of TB. The quality of the imputation can be improved by adding variables outside the analysis [18](#jia225392-bib-0018){ref-type="ref"}, therefore in addition to the outcome and the covariates used in the analysis, we also considered the date of TB treatment start, IeDEA region, setting, level of care for imputation. We ran the model on 20 imputed datasets for each analysis and used the Rubin rule to pool the estimates. All analyses were performed in STATA (version 14.1, Stata Corporation, Texas, USA).

2.5. Ethics statement {#jia225392-sec-0011}
---------------------

Local institutional review board or ethics committee approval was obtained at all local study sites. Informed consent was obtained where requested per local regulations. The Vanderbilt University Medical Center Institutional Review Board, Nashville, Tennessee (USA), and the Cantonal Ethics Committee Bern (Switzerland) approved the analyses for this specific project.

3. Results and discussion {#jia225392-sec-0012}
=========================

3.1. Study sites and patient characteristics {#jia225392-sec-0013}
--------------------------------------------

The 2695 HIV‐positive TB patients participating in this study were treated at 22 ART programmes in 19 countries (Figure [1](#jia225392-fig-0001){ref-type="fig"}). Eighteen sites were urban, three were peri‐urban and one site was rural. The level of care was mostly tertiary, at 17 sites, followed by secondary at four sites and primary at one site. For TB diagnostics a free‐of‐charge cost model was available at 11 of the 22 sites, a cost sharing model was available at 10 of the 22 sites and one site had a mixed cost model.

The median patient age was 35.5 years (interquartile range (IQR) 29.9 to 42.8), and 1102 patients (40.9%) were female. Among the 2695 patients, 1930 had PTB (71.6%) and 765 had EPTB (28.4%); 131 patients (4.9% overall) had both. At the time of TB diagnosis, 1270/2965 (47.1%) TB patients had not started ART and 763/2695 (28.3%) TB patients were on ART; the ART status of the remaining patients was unknown. Of the TB patients on ART, 342/763 (44.8%) were more than six months on ART before TB diagnosis and 421/763 (55.2%) were six or less months on ART. Among the 765 EPTB patients, the most frequent sites of disease were the lymph nodes (24.4%), pleura (14.2%), abdomen (11.1%), and meninges (6.3%). Complete patient characteristics are given in Table [1](#jia225392-tbl-0001){ref-type="table"}. When stratifying CD4 cell counts at the time of TB treatment (0 to 49 cells/μL; 50 to 199 cells/μL; ≥200 cells/μL; missing CD4 values), the frequencies of sites of EPTB manifestations remained similar over all groups.

###### 

Characteristics of HIV‐positive patients diagnosed with pulmonary tuberculosis and extrapulmonary tuberculosis at the start of TB treatment in 22 antiretroviral treatment programmes from lower income countries

                                                              All                   PTB                   EPTB                                        
  ----------------------------------------------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  Total, n (%)                                                2695 (100)            1930 (71.6)           765 (28.4)            131 (4.9)             634 (23.5)
  Age, year                                                                                                                                           
  16 to 29                                                    588 (21.8)            414 (21.4)            174 (22.8)            28 (21.4)             146 (23.0)
  30 to 39                                                    1105 (41.0)           793 (41.1)            312 (40.8)            59 (45.0)             253 (39.9)
  40 to 49                                                    696 (25.8)            503 (26.1)            193 (25.2)            35 (26.7)             158 (24.9)
  50                                                          306 (11.4)            220 (11.4)            86 (11.2)             9 (6.9)               77 (12.2)
  Sex, n (%)                                                                                                                                          
  Male                                                        1593 (59.1)           1134 (58.8)           459 (60.0)            90 (68.7)             369 (58.2)
  Female                                                      1102 (40.9)           796 (41.2)            306 (40.0)            41 (31.3)             265 (41.8)
  BMI at start of TB treatment kg/m^2^, median (IQR)          18.7 (16.8 to 20.9)   18.6 (16.7 to 20.8)   18.8 (16.9 to 21.1)   18.1 (16.4 to 19.8)   18.9 (17.0 to 21.4)
  *No. of observations (%)*                                   2115 (78.5)           1553 (80.5)           562 (73.5)            82 (62,6)             480 (75.7)
  CD4 count at TB treatment start, median (IQR), cells/μL     114 (40 to 248)       124 (45 to 263)       92 (32 to 212)        55 (19 to 129)        105 (34 to 228)
  *No. of observations (%)*                                   2196 (81.5)           1575 (81.6)           621 (81.2)            108 (82.4)            513 (80.9)
  ART status at TB diagnosis                                                                                                                          
  Not on ART                                                  1270 (47.1)           936 (48.5)            334 (43.7)            51 (38.9)             283 (44.6)
  On ART                                                      763 (28.3)            599 (31.0)            164 (21.4)            12 (9.2)              152 (24.0)
  6 + months at TB diagnosis                                  342 (12.7)            268 (13.9)            74 (9.7)              4 (3.1)               70 (11.0)
  \<6 months at TB diagnosis                                  421 (15.6)            331 (17.2)            90 (11.8)             8 (6.1)               82 (12.9)
  Missing                                                     662 (24.7)            395 (20.5)            267 (34.9)            68 (51.9)             199 (31.4)
  Previous history of TB, n (%)                                                                                                                       
  Yes                                                         55 (2.0)              37 (1.9)              18 (2.4)              3 (2.3)               15 (2.4)
  No                                                          2304 (85.5)           1705 (88.3)           599 (78.3)            82 (62.6)             517 (81.5)
  Unknown                                                     336 (12.5)            188 (9.7)             148 (19.3)            46 (35.1)             102 (16.1)
  TB treatment outcomes, n (%)                                                                                                                        
  Treatment success[a](#jia225392-note-0002){ref-type="fn"}   1908 (70.8)           1383 (71.7)           525 (68.6.9)          75 (57.3)             450 (71.0)
  Treatment failed                                            15 (0.6)              13 (0.7)              2 (0.3)               1 (0.8)               1 (0.2)
  Died                                                        281 (10.4)            194 (10.1)            87 (11.4)             13 (9.9)              74 (11.7)
  Lost to follow‐up (default)                                 136 (5.0)             100 (5.2)             36 (3.2)              16 (12.2)             20 (3.2)
  Not evaluated[b](#jia225392-note-0002){ref-type="fn"}       355 (13.2)            240 (12.4)            113 (14.0)            24 (18.3)             89 (14.0)
  Organs involved in EPTB, n (%)                                                                                                                      
  Lymph nodes[c](#jia225392-note-0002){ref-type="fn"}         187 (6.9)             ‐                     187 (24.4)            31 (23.7)             156 (24.6)
  Pleura                                                      109 (4.0)             ‐                     109 (14.2)            15 (11.5)             94 (14.8)
  Abdomen                                                     85 (3.2)              ‐                     85 (11.1)             13 (9.9)              72 (11.4)
  Meninges                                                    48 (1.8)              ‐                     48 (6.3)              10 (7.6)              38 (6.0)
  Miliary[d](#jia225392-note-0002){ref-type="fn"}             32 (1.2)              ‐                     32 (4.2)              10 (7.6)              22 (3.5)
  Joints and/or bones                                         22 (0.8)              ‐                     22 (2.9)              4 (3.1)               18 (2.8)
  Pericardium                                                 13 (0.5)              ‐                     13 (1.7)              3 (2.3)               10 (1.6)
  Genitourinary tract                                         3 (0.1)               ‐                     3 (0.4)               1 (0.8)               2 (0.3)
  Larynx                                                      1 (\<0.1)             ‐                     1 (0.1)               ‐                     1 (0.2)
  Unknown                                                     265 (9.8)             ‐                     265 (34.6)            44 (33.6)             221 (34.9)
  IeDEA region, n (%)                                                                                                                                 
  Caribbean/C‐S America                                       295 (11.0)            160 (8.3)             135 (17.6)            42 (32.1)             93 (14.7)
  Asia‐Pacific                                                327 (12.1)            176 (9.1)             151 (19.7)            45 (34.4)             106 (16.7)
  West Africa                                                 163 (6.0)             87 (4.5)              76 (9.9)              30 (22.9)             46 (7.3)
  Central Africa                                              394 (14.6)            262 (13.6)            132 (17.3)            9 (6.9)               123 (19.4)
  East Africa                                                 1511 (56.1)           1244 (64.5)           267 (34.9)            4 (3.1)               263 (41.5)
  Southern Africa                                             5 (0.2)               1 (\<0.1)             4 (0.5)               1 (0.8)               3 (0.5)

ART, antiretroviral therapy; BMI, body mass index; Caribbean/C‐S America, Caribbean, Central and South America; EPTB, extrapulmonary tuberculosis; IQR, interquartile range; MDR, multidrug‐resistant; n, number; PTB, pulmonary tuberculosis; TB, Tuberculosis.

^a^Treatment success includes cured patients and patients who completed TB treatment; ^b^not evaluated includes on treatment, transfer out, and unknown; ^c^extra‐ and intrathoracic; ^d^miliary TB defined as EPTB.

John Wiley & Sons, Ltd

3.2. Diagnostics of EPTB and PTB {#jia225392-sec-0014}
--------------------------------

Diagnostic capabilities varied according to sites. Sputum smear microscopy was available at all sites. Culture was not available at one site each in East Africa (1/4) and Central Africa (1/4), and Xpert MTB/RIF was not available at half of the sites: two in East Africa (2/4), three in Central Africa (3/4), two in West Africa (2/4), one in Asia‐Pacific (1/5), and three in Caribbean, Central and South America (3/4) and other NAATS were not available in half of the sites: two in East Africa (2/4), two in Central Africa (2/4), two in West Africa (2/4), three in Asia‐Pacific (3/5), and two in Caribbean, Central and South America (2/4). Bacteriological confirmation of PTB, EPTB only, and PTB/EPTB was sought in varying proportions in the three groups, and test results in groups varied as well. A confirmatory bacteriological test was performed in 438 of 765 EPTB (including mixed PTB/EPTB) patients (57.3%) and 1557 of 1930 PTB patients (80.7%). Bacteriological confirmation by any test (positive test result) was obtained in 183 of those 438 EPTB patients (41.8%), 103 of 334 patients with only EPTB (30.8%) and 807 of the 1557 PTB patients (51.8%). The diagnoses of the remaining EPTB and PTB patients who were not tested or whose test results were negative were based on clinical criteria (Table [2](#jia225392-tbl-0002){ref-type="table"}).

###### 

Diagnostic testing (smear microscopy, culture, Xpert MTB/RIF and/or nucleic acid amplification tests) of PTB and EPTB in HIV‐positive patients: proportion of bacteriologically confirmed results (any positive result/any confirmatory test performed (positive and negative)), and proportions by specific diagnostic tests (smear microscopy, culture and Xpert MTB/RIF)

                            Total        Bacteriological confirmation[a](#jia225392-note-0004){ref-type="fn"}   Smear microscopy confirmation   Culture confirmation   Xpert MTB/RIF confirmation
  ------------------------- ------------ ---------------------------------------------------------------------- ------------------------------- ---------------------- ----------------------------
  Site of disease                                                                                                                                                      
  PTB                       1930 (100)   807/1557 (51.8)                                                        805/1531 (52.6)                 95/191 (49.7)          53/77 (68.8)
  EPTB                      765 (100)    183/438 (41.8)                                                         118/416 (28.4)                  75/133 (56.4)          23/35 (65.7)
  EPTB only                 634 (100)    103/334 (30.8)                                                         58/317 (18.3)                   43/84 (51.2)           12/20 (60.0)
  Mixed PTB/EPTB            131 (100)    80/104 (76.9)                                                          60/99 (60.6)                    32/49 (65.3)           11/15 (73.3)
  Organs involved in EPTB                                                                                                                                              
  Lymph nodes               187 (100)    77/131 (58.8)                                                          46/115 (40.0)                   17/32 (53.1)           15/18 (75.0)
  Meninges                  48 (100)     14/29 (48.3)                                                           5/22 (22.7)                     4/7 (57.1)             4/4 (100)
  Abdomen                   85 (100)     18/58 (31.0)                                                           9/45 (20.0)                     3/8 (27.5)             1/1 (100)
  Pleura                    109 (100)    14/49 (28.6)                                                           7/47 (14.9)                     3/6 (50.0)             ‐
  Joint/bones               22 (100)     6/12 (50.0)                                                            4/11 (36.4)                     3/4 (75.0)             0/1 (0)
  Miliary                   32 (100)     5/20 (25.0)                                                            3/17 (17.6)                     5/5 (100)              1/1 (100)
  Other                     17 (100)     3/10 (30.0                                                             2/9 (22.2)                      1/1 (100)              1/1 (100)
  Unknown                   265 (100)    58/154 (37.7)                                                          42/150 (28.0)                   39/70 (55.7)           1/9 (11.1)

EPTB, extrapulmonary tuberculosis; n, numbers; PTB, pulmonary tuberculosis.

Bacteriological confirmation was defined as confirmed if any diagnostic test result was positive (smear microscopy, culture, Xpert MTB/RIF and/or nucleic acid amplification tests).

John Wiley & Sons, Ltd

Among EPTB patients, smear microscopy was the most frequently performed diagnostic test (in 416 of 765 patients, 54.4%) and Xpert MTB/RIF was the least frequently performed diagnostic test (in 35 of 584 patients, 6.0%), but had the highest proportion of bacteriological confirmation (in 23 of 35 patients, 65.7%). The highest proportion of bacteriological confirmation was found among patients with lymph node TB, (in 77 of 131 patients, 58.8%).

3.3. Patient factors associated with LTFU and mortality {#jia225392-sec-0015}
-------------------------------------------------------

In a multivariate model, LTFU during TB treatment was equivalent in EPTB patients' (including both PTB/EPTB) compared to PTB patients (aOR 0.92, 95% CI 0.36 to 2.32). It was also equivalent in EPTB patients' only compared to PTB patients (aOR 0.58, 95% CI 0.30 to 1.13). However, patients with both PTB/EPTB had at higher odds for LTFU compared to PTB patients (aOR 2.59, 95% CI 1.06 to 6.32, Table [3](#jia225392-tbl-0003){ref-type="table"}). EPTB mortality was similar to that of PTB (aOR 1.03, 95% CI 0.84 to 1.27; Table [3](#jia225392-tbl-0003){ref-type="table"}). However, TB meningitis was associated with increased mortality (aOR 1.85, 95% CI 1.00 to 3.10) compared to PTB, and overall mortality was also higher in patients with CD4 cell counts \<50 cells/μL compared to those with CD4 cell counts ≥200 cells/μL (aOR 2.60, 95% CI 1.46 to 4.64; Table [3](#jia225392-tbl-0003){ref-type="table"}). Sensitivity analyses (Table [3](#jia225392-tbl-0003){ref-type="table"}) considering patients LTFU as having died showed similar results. From a separate model, bacteriological confirmation was associated with reduced mortality among PTB patients (aOR 0.68, 95% CI 0.61 to 0.76) and EPTB patients (aOR 0.32 95% CI 0.13 to 0.79) compared to all other TB patients with a negative test result.

###### 

Risk factors for lost to follow‐up and mortality during tuberculosis treatment in HIV‐positive patients diagnosed with extrapulmonary and pulmonary TB

  Variable                                                  No. of patients   Lost to follow‐up (LTFU)   Mortality                                                                                                                         
  --------------------------------------------------------- ----------------- -------------------------- --------------------- --------- --------------------- ------- ------------ ---------------------- --------- --------------------- ---------
  Age, years                                                                                                                   0.15                            0.007                                       0.01                            \<0.001
  16 to 29                                                  494               38 (7.7)                   1                               1                             43 (8.7)     1                                1                     
  30 to 39                                                  966               58 (6.0)                   0.77 (0.50 to 1.17)             0.79 (0.54 to 1.16)           109 (11.3)   1.33 (0.92 to 1.94)              1.20 (0.85 to 1.71)   
  40 to 49                                                  617               29 (4.7)                   0.59 (0.36 to 0.97)             0.65 (0.49 to 0.85)           90 (14.6)    1.79. (1.22 to 2.63)             1.80 (0.84 to 3.87)   
  ≥50                                                       263               11 (4.2)                   0.57 (0.29 to 1.12)             0.61 (0.24 to 1.56)           39 (14.8)    1.83 (1.15 to 2.90)              1.95 (1.26 to 3.00)   
  Sex                                                                                                                          0.39                            0.55                                        0.95                            0.68
  Female                                                    953               51 (5.4)                   1                               1                             114 (12.0)   1                                1                     
  Male                                                      1387              85 (6.1)                   1.17 (0.82 to 1.67)             1.14 (0.74 to 1.75)           167 (12.0)   1.00 (0.78 to 1.29)              0.89 (0.50 to 1.56)   
  BMI at start of TB treatment, kg/m^2^                     2340              ‐                          0.91 (0.85 to 0.97)   0.004     0.88 (0.81 to 0.96)   0.003   ‐            0.96 (0.93 to 1.01)    0.13      0.98 (0.94 to 1.01)   0.19
  History of TB                                                                                                                0.57                            0.71                                        0.47                            0.87
  No                                                        2293              132 (5.8)                  1                               1                             274 (11.9)   1                                1                     
  Yes                                                       47                4 (8.5)                    1.37 (0.47 to 3.94)             1.30 (0.32 to 5.23)           7 (14.9)     1.36 (0.59 to 3.12)              0.91 (0.29 to 2.87)   
  ART status at TB diagnosis                                                                                                   0.13                            0.20                                        0.94                            0.28
  Not on ART                                                1660              104 (6.3)                  1                               1                             200 (12.0)   1                                1                     
  On ART                                                    680               32 (4.7)                   0.73 (0.49 to 1.10)             0.75 (0.48 to 1.17)           81 (11.9)    0.99 (0.75 to 1.30)              1.21 (0.85 to 1.74)   
  CD4 count at TB treatment start, cells/μL                                                                                    0.19                            0.024                                       \<0.001                         0.008
  0 to 49                                                   646               40 (6.2)                   1.36 (0.84 to 2.21)             1.26 (0.94 to 1.69)           115 (17.8)   2.27 (1.61 to 3.19)              2.60 (1.46 to 4.64)   
  50 to 199                                                 829               59 (7.1)                   1.51 (0.97 to 2.34)             1.46 (1.09 to 1.97)           89 (10.7)    1.25 (0.89 to 1.75)              1.38 (0.99 to 1.93)   
  ≥200                                                      865               39 (4.5)                   1                               1                             77 (8.9)     1                                1                      
  Site of disease                                                                                                              0.82                            0.86                                        0.21                            0.75
  PTB                                                       1688              100 (5.9)                  1                               1                             194 (11.5)   1                                1                     
  EPTB                                                      652               36 (5.5)                   0.96 (0.65 to 1.41)             0.92 (0.36 to 2.32)           87 (13.3)    1.19 (0.90 to 1.56               1.03 (0.84 to 1.27)   
  EPTB only^1^                                              546               20 (3.7)                   0.60 (0.37 to 0.99)   0.044     0.58 (0.30 to 1.13)   0.12    74 (13.6)    1.21 (0.91 to 1.61)    0.19      1.04 (0.87 to 1.71)   0.69
  Mixed PTB/EPTB[a](#jia225392-note-0006){ref-type="fn"}    106               16 (15.9)                  3.03 (1.74 to 5.29)   \<0.001   2.59 (1.06 to 6.32)   0.037   13 (12.3)    1.07 (0.59 to 1.96)    0.81      1.03 (0.62 to 1.71)   0.92
  Organs involved[b](#jia225392-note-0006){ref-type="fn"}                                                                      0.72                            0.67                                        0.14                            \<0.001
  Lungs                                                     1772              116 (6.5)                  1                               1                             207 (11.7)   1                                1                     
  Meninges                                                  43                1 (2.3)                    1.71 (0.60 to 4.89)             1.76 (0.46 to 6.67)           10 (23.3)    2.28 (1.10 to 4.69)              1.85 (1.00 to 3.10)   
  Miliary                                                   26                2 (7.7)                    1.39 (0.32 to 5.98)             1.52 (0.38 to 6.02            2 (7.7)      0.63 (0.15 to 2.67)              0.74 (0.31 to 1.74)   
  Other                                                     449               18 (4.0)                   1.12 (0.73 to 1.68)             1.10 (0.36 to 3.41)           62 (13.8)    1.05 (0.77 to 1.42)              0.87 (0.64 to 1.17)   

ART, antiretroviral therapy; BMI, body mass index; 95% Cl, 95% confidence interval; ART, antiretroviral therapy; EPTB, extrapulmonary tuberculosis; LTFU, lost to follow‐up; OR, odds ratio; PTB, pulmonary tuberculosis; TB, tuberculosis.

The main logistic regression model was adjusted for age, sex, BMI at start of TB treatment, previous history of TB, CD4 cell count at TB treatment start, ART status at TB diagnosis, and site of disease, taking into account heterogeneity across regions (clustering by treatment programmes). The model was based on 2340 patients since patients with TB treatment outcome defined as "not evaluated" (n = 355) were excluded from the analysis. The reference category is indicated with 1.

^a^These estimates were obtained from a separate model (n = 2340) comparing PTB versus EPTB only and mixed PTB/EPTB and was adjusted for age, sex, BMI at start of TB treatment, previous history of TB, CD4 cell count at TB treatment start, ART status at TB diagnosis, and taking into account heterogeneity across regions (clustering by treatment programmes). The reference category is indicated with 1; ^b^these estimates were obtained from a separate model (n = 2340) comparing involved organs lungs versus meninges, miliary, and other organs and was adjusted for age, sex, BMI at start of TB treatment, previous history of TB, CD4 cell count at TB treatment start, ART status at TB diagnosis, and taking into account heterogeneity across regions (clustering by treatment programmes). The reference category is indicated with 1.
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The lymph nodes, pleura, abdomen, and meninges were the most frequently involved organs in this large, multicohort study of HIV‐positive EPTB patients treated in ART programmes in sub‐Saharan Africa, Asia‐Pacific, and Caribbean, Central and South America. Diagnosis were mainly based on clinical criteria, and bacteriological confirmation was seen less frequently in EPTB than PTB patients. Mortality was reduced among EPTB patients and PTB patients with a positive diagnostic test result compared to all other TB patients with a negative result. The observation that CD4 cell count in patients with EPTB was frequently lower than that of PTB patients was similar to the report of a South African study, that found that EPTB was generally more common in HIV‐positive patients with lower CD4 cell counts, and three times more frequent among those with HIV and a CD4 count \<50 cells/μL than among HIV‐negative individuals [4](#jia225392-bib-0004){ref-type="ref"}. Similarly, the predominating involvement of the lymph nodes that we observed is consistent with previous publications on the presentation of EPTB in HIV‐positive adults [19](#jia225392-bib-0019){ref-type="ref"}, [20](#jia225392-bib-0020){ref-type="ref"}, [21](#jia225392-bib-0021){ref-type="ref"}, [22](#jia225392-bib-0022){ref-type="ref"}, [23](#jia225392-bib-0023){ref-type="ref"}, [24](#jia225392-bib-0024){ref-type="ref"}.

The diagnosis of TB is more challenging in HIV‐positive than in HIV‐negative patients. In PTB, this is due to reduced lung cavitation and lower bacterial load in sputum [25](#jia225392-bib-0025){ref-type="ref"}, [26](#jia225392-bib-0026){ref-type="ref"}, [27](#jia225392-bib-0027){ref-type="ref"}, [28](#jia225392-bib-0028){ref-type="ref"}. In line with previously published results, we observed that smear microscopy was the most commonly used diagnostic tool, even when other diagnostic modalities were available [16](#jia225392-bib-0016){ref-type="ref"}. We further observed that bacteriological confirmation (positive smear microscopy, culture or Xpert MTB/RIF result) was associated with reduced mortality in PTB and EPTB patients compared to TB patients with a negative result. A study from Malawi showed similar results, but also found increased mortality among EPTB patients with a smear‐negative result [29](#jia225392-bib-0029){ref-type="ref"}. A systematic review explained the reduced mortality in bacteriologically confirmed PTB cases by showing that smear‐ and culture‐negative disease is typical of advance HIV immunosuppression compared to smear‐positive TB patients with a less compromised immune system [30](#jia225392-bib-0030){ref-type="ref"}.

Among the EPTB patients for whom a bacteriological confirmation test was performed, only 42% were confirmed positive. Bacteriological confirmation is challenging due to EPTB\'s paucibacillary nature, in tissue, body fluid, or cerebrospinal fluid and the need for invasive specimen collection for microbiological diagnosis by biopsy or fine needle aspiration [7](#jia225392-bib-0007){ref-type="ref"}, [8](#jia225392-bib-0008){ref-type="ref"}, [9](#jia225392-bib-0009){ref-type="ref"}. Mycobacterial culture and Xpert MTB/RIF have been shown to reliably diagnose EPTB, but are still rarely used in resource‐limited settings, even when available [13](#jia225392-bib-0013){ref-type="ref"}, [16](#jia225392-bib-0016){ref-type="ref"}. From a programmatic perspective, the introduction of new diagnostics can indeed increase the proportion of bacteriological confirmed TB patients, as shown by a study from Cape Town, South Africa [31](#jia225392-bib-0031){ref-type="ref"}, but this may depend on the clinical setting [32](#jia225392-bib-0032){ref-type="ref"}. The newly developed, next generation Xpert MTB/RIF Ultra assay has a higher sensitivity and similar specificity than the first generation Xpert MTB/RIF assay [33](#jia225392-bib-0033){ref-type="ref"}, and seems to be particularly useful in EPTB and paediatric TB [34](#jia225392-bib-0034){ref-type="ref"}.

While overall mortality was similar in PTB and EPTB patients, the mortality of HIV‐positive patients with TB meningitis was greater than that of HIV‐positive patients with PTB. This is in accord with a review that reported mortality up to 69% for TB meningitis in low‐income countries [6](#jia225392-bib-0006){ref-type="ref"}. We observed no difference in the odds of being LTFU during treatment among PTB compared to EPTB patients, which is in line with a Nigerian study [35](#jia225392-bib-0035){ref-type="ref"}. However, we found that patients with only EPTB showed lower and mixed PTB/EPTB cases slightly increased risk of LTFU compared to PTB. This could be explained by the fact that the patients with mixed PTB/EPTB diagnosis are too sick to return to the clinic, or might even have died at home. A recent study from Botswana also reported an increased risk for LTFU during treatment in EPTB patients (including mixed PTB/EPTB cases) compared to PTB patients [36](#jia225392-bib-0036){ref-type="ref"}.

The main limitation of our study was its potential for misclassification bias. EPTB might have been underestimated due to the limited availability of diagnostic capacities [16](#jia225392-bib-0016){ref-type="ref"} and the clinical practice of not pursuing further diagnoses once a PTB diagnosis has been established. Another limitation of the study was the heterogeneity of the participating ART programmes in terms of TB and HIV treatment, availability of supportive care [16](#jia225392-bib-0016){ref-type="ref"} as well as lack of data on opportunistic infections other than TB. Further analysis of treatment outcomes by diagnostic method was not possible due to the small numbers. Although we could not assess the vital status of those LTFU, the sensitivity analysis that we conducted to assess the potential impact of misclassification of death as lost to follow‐up did not show any differences in the main outcomes. In spite of these potential limitations, our study provides important evidence on the limited diagnostic capacities available for EPTB at ART programmes in LMIC, and is one of few studies investigating EPTB in this context.

4. Conclusions {#jia225392-sec-0016}
==============

Diagnosis of EPTB in ART programmes in LMIC is based mainly on clinical symptoms, and the introduction of molecular assays is still challenging despite major efforts. We conclude that greater access to diagnostic services could improve diagnosis, increase the number of diagnosed EPTB and improve clinical management of EPTB as well as treatment outcomes.
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